ZIMMER BIOMET HOLDINGS, INC. (ZBH) Form 10-Q — Aug 5, 2026
Zimmer Biomet's Q2 2026 net sales rose 4.8% year-over-year to $2,177.0 million, with net earnings up roughly 30% to $198.3 million and diluted EPS of $1.03 versus $0.77 a year ago. First-half sales grew 7.0% to $4,263.7 million, led by the Paragon 28 acquisition, ROSA Robot and bone cement sales, and new product introductions. The company reaffirmed 2026 guidance of 3.9% to 4.9% net sales growth and expects operating profit to increase, helped by an approximately $30 million benefit from probable U.S. tariff refunds, restructuring savings, and lower acquisition costs.
Key figures
- Eps
- 1.03
- Revenue
- 2177
- Guidance
- 2026 net sales growth of 3.9% to 4.9% year-over-year (Paragon 28 ~1.1 pts, FX ~0.5 pts); operating profit expected to increase vs 2025
- Net Income
- 198.3
- Total Debt
- 7479
- Revenue Yoy
- 4.8% (Q2 2026 YoY); 7.0% for first half
- Total Assets
- 22797.8
- Cash Position
- 410
- Shares Outstanding
- 190737689
- Current debt
- 1201.5
- Q2 repurchases
- 2,917,831 shares at average $84.60
- Ieepa tariffs paid
- approximately $77 million; ~$30 million COGS reduction recognized on probable refunds
- Litigation accrual
- 137.9
- Q2 operating profit
- 326.1
- H1 share repurchases
- 500.8
- Six month net income
- 436.5
- Effective tax rate q2
- 21.8% vs 31.7% prior year
- Six month diluted eps
- 2.25
- Restructuring 2025 plan
- ~$155 million total pre-tax charges by end of 2027 (~$147 million incurred); ~$175 million targeted annual savings
- Investment fund commitment
- up to $300 million callable over four years
- Max contingent consideration
- $0 to $720 million payable through 2031
- Quarterly dividend per share
- 0.24
- Six month operating cash flow
- 807.2
- Buyback authorization remaining
- 1003.1
Price after filing
Close on the filing date to close N calendar days later (from $95.81). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.